The hard part isn’t the science.
It’s everything after it.

That’s why we built Tribal: one platform that carries an asset from the first search to a filed submission, so your budget goes into the molecule instead of the paperwork around it.

Three colleagues working through a ranked asset shortlist shown on a wall screen

This is the
Tribal platform

One workspace, from search to submission

Your source data, your documents and your team sit in one place, where each step feeds the next. Search the asset universe, draft to eCTD structure, and check every claim against the file it came from, without moving between four tools to do it.

  • Every claim traced to its source
  • Built to eCTD from the first draft
  • Gaps flagged before a reviewer finds them
  • One audit trail across the whole programme

Ask in plain English or screen by field. Tribal reads public, licensed and internal sources together and returns a ranked shortlist with the evidence behind every score.

Screen · rare haematology42 assets
Query

De-risked assets with Phase 2 readouts, under-partnered, US & EU rights available

AssetPhaseModalityScore
TB-2071Phase 2Small molecule94
FerristatPhase 1Biologic88
AV-118PreclinicalSmall molecule81

Draft in the
document editor

Say what you want changed

Ask for a change in a sentence. Tribal rewrites the affected passages in place and shows them as tracked edits, with the source for anything it adds. Nothing enters the dossier until you accept it.

  • Edits arrive redlined, never silently applied
  • Cross-references and tables update together
  • Every insertion carries its source
Ask

Add the 10 mg/kg dose group and state the NOAEL for the 28-day study.

2.6.6 Toxicology written summary

Rats were administered 13F-SFA by oral gavage once daily for 28 days at dose levels of 0 (vehicle control), 10, 30 and 120 mg/kg/day.

No treatment-related findings were observed in clinical chemistry or histopathology at or below 120 mg/kg/day. The NOAEL could be calculated to be 150 mg/kg. The NOAEL was 120 mg/kg/day, based on the absence of adverse findings at this dose.

Source 28d_tox_study.pdf · p.14, Table 8

2 changes Reject Accept both

See it on
your own asset

Bring one programme. We will show you what comes back.

Schedule a demo